Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.93
(-0.5%)
HKD 5.93
(-0.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.4 Billion HKD | -23.93% |
| 2022 | 4.47 Billion HKD | 22.76% |
| 2021 | 3.64 Billion HKD | 52.64% |
| 2020 | 2.38 Billion HKD | 15.67% |
| 2019 | 2.06 Billion HKD | -21.91% |
| 2018 | 2.64 Billion HKD | -14.34% |
| 2017 | 3.08 Billion HKD | 2.25% |
| 2016 | 3.01 Billion HKD | -7.99% |
| 2015 | 3.28 Billion HKD | 85.41% |
| 2014 | 1.76 Billion HKD | 5.86% |
| 2013 | 1.67 Billion HKD | 17.6% |
| 2012 | 1.42 Billion HKD | 94.15% |
| 2011 | 732.06 Million HKD | 111.14% |
| 2010 | 346.71 Million HKD | 145.56% |
| 2009 | 141.19 Million HKD | -1.78% |
| 2008 | 143.75 Million HKD | 34.69% |
| 2007 | 106.73 Million HKD | 97.57% |
| 2006 | 54.02 Million HKD | 24.3% |
| 2005 | 43.46 Million HKD | -43.04% |
| 2004 | 76.3 Million HKD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.54 Billion HKD | 0.0% |
| 2023 Q4 | 3.4 Billion HKD | 0.0% |
| 2023 Q2 | 4.23 Billion HKD | 0.0% |
| 2023 FY | 3.4 Billion HKD | -23.93% |
| 2022 Q4 | 4.47 Billion HKD | 0.0% |
| 2022 Q2 | 3.58 Billion HKD | 0.0% |
| 2022 FY | 4.47 Billion HKD | 22.76% |
| 2021 Q2 | 2.89 Billion HKD | 0.0% |
| 2021 FY | 3.64 Billion HKD | 52.64% |
| 2021 Q4 | 3.64 Billion HKD | 0.0% |
| 2020 Q4 | 2.38 Billion HKD | 0.0% |
| 2020 Q2 | 2.74 Billion HKD | 0.0% |
| 2020 FY | 2.38 Billion HKD | 15.67% |
| 2019 FY | 2.06 Billion HKD | -21.91% |
| 2019 Q4 | 2.06 Billion HKD | 0.0% |
| 2019 Q2 | 2.45 Billion HKD | 0.0% |
| 2018 Q2 | 3.54 Billion HKD | 0.0% |
| 2018 Q4 | 2.62 Billion HKD | 0.0% |
| 2018 FY | 2.64 Billion HKD | -14.34% |
| 2017 Q4 | 2.99 Billion HKD | 0.0% |
| 2017 FY | 3.08 Billion HKD | 2.25% |
| 2017 Q2 | 3.04 Billion HKD | 0.0% |
| 2016 Q4 | 2.92 Billion HKD | 0.0% |
| 2016 Q2 | 3.04 Billion HKD | 0.0% |
| 2016 FY | 3.01 Billion HKD | -7.99% |
| 2015 Q4 | 3.18 Billion HKD | 0.0% |
| 2015 FY | 3.28 Billion HKD | 85.41% |
| 2015 Q2 | 2.81 Billion HKD | 0.0% |
| 2014 Q4 | 1.76 Billion HKD | 0.0% |
| 2014 FY | 1.76 Billion HKD | 5.86% |
| 2014 Q2 | 1.93 Billion HKD | 0.0% |
| 2013 Q4 | 1.67 Billion HKD | 0.0% |
| 2013 Q2 | 1.85 Billion HKD | 0.0% |
| 2013 FY | 1.67 Billion HKD | 17.6% |
| 2012 FY | 1.42 Billion HKD | 94.15% |
| 2012 Q2 | 1.28 Billion HKD | 0.0% |
| 2012 Q4 | 1.42 Billion HKD | 0.0% |
| 2011 Q4 | 732.06 Million HKD | 0.0% |
| 2011 Q2 | 681.92 Million HKD | 0.0% |
| 2011 FY | 732.06 Million HKD | 111.14% |
| 2010 Q2 | 479.11 Million HKD | 0.0% |
| 2010 FY | 346.71 Million HKD | 145.56% |
| 2010 Q4 | 346.71 Million HKD | 0.0% |
| 2009 Q4 | 141.19 Million HKD | 0.0% |
| 2009 FY | 141.19 Million HKD | -1.78% |
| 2009 Q2 | 159.6 Million HKD | 0.0% |
| 2008 Q4 | 143.75 Million HKD | 0.0% |
| 2008 FY | 143.75 Million HKD | 34.69% |
| 2007 FY | 106.73 Million HKD | 97.57% |
| 2006 FY | 54.02 Million HKD | 24.3% |
| 2005 FY | 43.46 Million HKD | -43.04% |
| 2004 FY | 76.3 Million HKD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -49888.833% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -2727.206% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -638.528% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -698922.382% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -1567.6% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -1057.817% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -919.774% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -701.431% |
| SSY Group Limited | 3.37 Billion HKD | -0.894% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -2451.769% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -354.275% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 96.035% |